Should try posting it to the SA article Lakeweed put out, see how far your free speech gets you. That horses bottom rejected three of four of my posts. If it posts that WOULD be HILARIOUS.
Madoff, LOL, Someone put a great list of about 50 indicted hedge funds yesterday. For the most part, if you do not make that list eventually, you are more clever, but not necessarily more honest than those guys. Like Bozo, BURIED and maybe the BOSS yanks the fund if redemptions go wild, so he BEGS RETAIL that HE SPITS on for help. He could be long today, tomorrow, RETAIL will not know. A leopard cannot change his spots in a heart beat, but he can be NET long in one minute if retail helped enough.
When he attacked the Streetsweeper he spit in their face for quoting a " retail investor " named Dr. Cannel. Dr. Cannell founded the US VITAMIN D council and is very long opko based on Rayaldy.
So when BOZO goes long he will have a new thesis, and SPIT on those who bailed him out, think hedge fund, think Bernie.
Why did he single out OPK??? Glad you asked. His fund was short OPKO from the 4's, and it was trading near 13, and his fund performance a quarter ago in this bull market was a meager 5-6% basically because bad shorts and bad picks. That said, HE WAS down nearly 200% on his original short play. I am fairly certain this is at least his second SA attack, one with the authors name anonymous used IDENTICAL terminology. So anyway, HE goes before his PEERS to get help at ROBIN HOOD, and puff short interest goes down. WHAT is a desperate hedge fund manager to do, ask retail to help so he can cover and run, Think hedge fund, BERNIE, HEDGE fund Bernie.
You are naive is you think OPKO is his only short, BUT IT was the one hurting HIM THE most, AND HE THANKS you if you followed his lead. The fund that was HANDED him TO BE MANAGED by his boss could have been taken away if you did not help him out of having a second HORRENDOUS year and underperforming in the past 5 years.
So think about it, you followed some bozo the clown who was down 200% to bail him out, who is the fool in that scenario.
They did not mention today that the Claros analyzer is now in ten languages, but did say roll out will be initially US, Mexico, and likely Spain, figure they follow that up with Brasil, Chile, Uruguay, Israel, Russia. If they can manage 30-40 million in US sales year one and average 7-8 million in those other countries 100 m year one is likely. Add that to the 100 a year they are doing now, it will be good.
Welcome back, hope your showing up is a good contrarian indicator. At least you always backed up your short thesis with a thoughtful argument. As far as cautious, you might be right, however, things can and do change when developing new products. What seems like an achievable timeline today can turn out to be wrong tomorrow. Sometimes the straight road has that curve up ahead and it is back to the drawing board.
There have been a few delays for sure, but in the BIG picture, they are on track.
They indirectly addressed one point made by Lakewood, about the Claros device error message. Like any SOFTWARE company before launch there are always bugs to iron out. This gets the testosterone and psa studies back on their timelines which is good, and a bit of Lakewood noise answered.
A second BIG thing which also addressed a Lakewood bash was that Doctors will not want to be bothered with the Claros device. They will hand the Drs the device and charge for the cards, BRILLIANT. Lot easier to walk in to make a sale when the Dr. does not NEED to lay out one thin dime, but is simultaneously told he can bill the insurance company for each test his nurse/assistant administers. The REAL money is in the tests, Opko likely breaks even on the device after the first 15-20 tests.
The GUY in charge of that division came from a company that dealt exclusively with urologists. He also stated clearly that a 20-30 person sales force can penetrate 80% of our target market in a reasonably short period of time. So I initially thought 2 years or longer to get psa, 4k, testosterone up to 50-60 penetration, the new strategy looks like it will be year one.
So the market is selling the news because he Frost and CO. did not do??? They answered two key bashes never mentioning the sleezeball by name.
The one big question out there and a bash is ROLAPITANT, and does it meet the end points of lasting longer and work as well or better than the current amed. If that phase 3 is good, it is good for opko, if it fails, and IT COULD, it hurts both TSRO and OPKO. That data is DUE any day. We will SEE.
I still stop by and post but only to throw an idea around. The slightly better than minimum wage group has taken over the robo job, so I visit the boards where I have other investments and reasonable conversation is still possible. This board is trash, bought and paid for, and Yahoo allows it. Maybe a dozen or so investors here and some FIRM has kicked them off the board. This board has no impact on investors, might scare off those new to the market, but if they R here looking for info, this is the WRONG place.
I thought this was a likely route for the claros device, the cassettes cost about 1.00 to make, will charge 10.00 per cassette is my guess. High high margin product. I missed parts of the call and it was at that exact moment the audio cast went down, have to wait for it to do a replay now.
The claros device and Lakwood saying how DOCs will not want to be bothered with it,... I though of my regular general practitioner and my last physical.. I said Doc, I either had bad heart burn or a heart attack. He had a CLAROS sized device in his examining room to MEASURE EKG. So he did an EKG right on the spot so I think an in office blood test has merit based on that one isolated small town experience.
I did not know anyone saw this post, it ended up 3-4 pages back in under one minute. So thanks JMHcsh.
The peculiar thing with the Lakeweed article is they did do a great job detailing the opko time line. Then drew conclusions about the time line to suit their needs. ALL longs should read it to get an understand of how rapidly Opko has grown, and how Dr. Frost put this company together. Frost has done a masterful job.
it is a good read. His conclusions are conclusions he needed to reach to validate his short thesis. From what I have read he has been short from the 4's, and has averaged up. As of Sept his Fund was only up about 5-6% and his short positions hurt the performance BADLY. Depending on the size of his short here, and how much retail bales him out, his hope is to bale out his lousy year at the longs expense. Amazing he did Robin Hood and got no real takers, so he GOES to that rag Seeking Alpha to get retail help, DESPERATE.
Over the years opko transitioned from an optics company, to a diagnostics/biotech/pharma company. Guess what over the past 8 years Opko has had a few missteps and drugs that failed while in development. Yes, TRUE, a BIOTECH many times has drugs in development that fail. Talking about these drugs by the CEO is not hyping the drug, hyping the company, or hyping the stock price as Lakeweed supposes. That is what a company has AN obligation to do. To keep share holders aware of the current state of the pipeline.
The BRILLIANCE of Dr. Frost can be seen in his investments. He buys into companies and buys technologies where he sees future potential. The RXII technology is one example which he JUST monetized this year, and Rolapitant which will bear fruit for years to come. Of course Lakewood SEES zero value there too. Rolapitant has one major competing drug, interesting is that the current CEO at TESARO worked for the company bringing that drug to market. Moulder did not buy rights to Rolapitant because he thought it was as good or less valuable than the drug his prior company developed, but had an edge, once a week, not daily.
Worthless, we will see, I am betting on Lonnie Moulder on that one, not Frost. I cannot even begin on Rayaldy, but Lakewoods lack of how that drug raises Vit d, while simultaneously lowers serum is MIND boggling. His answer, patients can go to Rite Aid.
Neshua, The whole study is outsourced, using a design North West designed and the FDA approved. The company is BLIND to all the data, how assigned etc. That said, there are things they could keep us abreast of like total enrollment. The best I can figure is this DCvaxL study started in q1-q2, 2011 but with only 2-4 cites taking patients, likely for money reasons. As they have done secondaries they have expanded the locations. The slow build out could be good for OS numbers if there is indeed an affect, but to be honest ALL the info needs be in one place to get a real handle. The earliest item I found :
Bethesda, Maryland, May 25, 2011 -- Northwest Biotherapeutics (OTC.BB: NWBO) today
announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the
doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the
Company’s ongoing 240-patient randomized, double blind, placebo controlled clinical trial of
DCVax® immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain
The Company previously announced 4 clinical sites for new enrollment into the ongoing trial,
located in Rochester, Cleveland, Detroit and Minneapolis. The Company has now added New
York City (NYU) and Los Angeles (UCLA). In addition, the Company is nearing completion on 4
further sites, in New Jersey, Michigan, Texas and Washington. As a result, the Company expects
to have a total of 10 clinical trial sites for new enrollment into its GBM brain cancer trial within
this calendar quarter. This will substantially exceed the Company’s projections in regard to the
expansion of the clinical trial this quarter. At least 5 further clinical sites are anticipated to be
added in the third quarter of this year, resulting in a total of 15 sites.
I believe that author was gray wolf. His research reads flawed after paragraph two or three. Simply put he questioned DDD's growth rate stating most was from acquisitions made with inflated stock. Of course that has been said of opko too. Problem with that junk is once you own a company that earnings and all subsequent is indeed organic.
The author anonymous house of cards used data and phraseology straight from Lakewood. There was also one about 8? months ago using lakes info claiming Dr. Frost was basically out to beat on small investors citing the company called Tiger Medias early days and the mess that happened there.
S&P 500 inclusion is more than market cap. The company needs 4 quarters of positive eps. So not a chance for at least a year.
Sometimes the robo guy is round the clock, but I too think it a Lakewood employee or two.